Search results
Results From The WOW.Com Content Network
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [ 2][ 3][ 4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [ 5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...
v. t. e. The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield[ 31 ] and Vaxzevria[ 1 ][ 32 ] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, [ 33 ][ 34 ][ 35 ] using as a vector the modified ...
The UK's most valuable company in terms of its market capitalisation of 189.4 billion pounds ($243.89 billion) has evolved significantly since CEO Pascal Soriot took over 12 years ago.
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria[6]and Covishield,[7]is a viral vector vaccine[8]produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8][9][10]Finland, Denmark, and Norway suspended the use of the Oxford ...
AstraZeneca’s COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease across all age groups in a late-stage study in the United ...
AstraZeneca's stock is up following its latest earnings report Thursday after the company reported $12.7 billion in revenue, beating consensus estimates of $11.8 billion in the first quarter of 2024.
More than 150 jobs will be created at the site in the United States to initially focus on manufacturing the cell therapies to enable clinical trials to be conducted, the company said, adding that ...
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases . Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic ...